Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "neutral" rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $70.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price target would suggest a potential downside of 11.58% from the stock's current price.
A number of other research analysts have also weighed in on GILD. Truist Financial raised their price target on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a "hold" rating in a research report on Thursday, August 15th. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $72.00 to $74.00 and gave the stock a "sector perform" rating in a research report on Wednesday, September 4th. Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Robert W. Baird reaffirmed a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday, June 20th. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $81.25.
Read Our Latest Research Report on Gilead Sciences
Gilead Sciences Stock Up 0.6 %
NASDAQ:GILD traded up $0.45 during trading hours on Monday, reaching $79.17. The company had a trading volume of 5,570,112 shares, compared to its average volume of 7,154,367. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The firm has a market cap of $98.57 billion, a price-to-earnings ratio of 220.97, a P/E/G ratio of 2.73 and a beta of 0.18. The business's 50-day simple moving average is $74.06 and its two-hundred day simple moving average is $70.55. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $87.86.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analysts' expectations of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. On average, equities analysts expect that Gilead Sciences will post 3.78 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Johanna Mercier sold 5,490 shares of the company's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 5,490 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Gilead Sciences
A number of institutional investors have recently made changes to their positions in GILD. Norges Bank purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $1,301,624,000. The Manufacturers Life Insurance Company boosted its position in Gilead Sciences by 78.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company's stock valued at $618,268,000 after buying an additional 3,362,505 shares during the period. Vanguard Group Inc. boosted its position in Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company's stock valued at $8,404,161,000 after buying an additional 2,910,147 shares during the period. Wellington Management Group LLP boosted its position in Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company's stock valued at $1,509,227,000 after buying an additional 2,350,550 shares during the period. Finally, Swedbank AB purchased a new stake in Gilead Sciences during the 1st quarter valued at $134,489,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
